The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Hedgehog‐EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour‐initiating pancreatic cancer cells
Open accessAbstract
Inhibition of Hedgehog (HH)/GLI signalling in cancer is a promising therapeutic approach. Interactions between HH/GLI and other oncogenic pathways affect the strength and tumourigenicity of HH/GLI. Cooperation of HH/GLI with epidermal growth factor receptor (EGFR) signalling promotes transformation and cancer cell proliferation in vitro . However, the in vivo relevance of HH‐EGFR signal integration and the critical downstream mediators are largely undefined. In this report we show that genetic and pharmacologic inhibition of EGFR signalling reduces tumour growth in mouse models of HH/GLI driven basal cell carcinoma (BCC). We describe HH‐EGFR cooperation response genes including SOX2, SOX9, JUN, CXCR4 and FGF19 that are synergistically activated by HH‐EGFR signal integration and required for in vivo growth of BCC cells and tumour‐initiating pancreatic cancer cells. The data validate EGFR signalling as drug target in HH/GLI driven cancers and shed light on the molecular processes controlled by HH‐EGFR signal cooperation, providing new therapeutic strategies based on combined targeting of HH‐EGFR signalling and selected downstream target genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
The EGF receptor is required for efficient liver regeneration
Natarajan, A., Wagner, B., & Sibilia, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704126104 · Cited by 320
Self-citation
Cited by
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604
The role of SOX family members in solid tumours and metastasis
Grimm, D., Bauer, J., Wise, P., Krüger, M., Simonsen, U., Wehland, M., Infanger, M., & Corydon, T. J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.004 · Cited by 487
SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells
Herreros-Villanueva, M., Zhang, J.-S., Koenig, A., Abel, E. V., Smyrk, T. C., Bamlet, W. R., de Narvajas, A. A.-M., Gomez, T. S., Simeone, D. M., Bujanda, L., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.23 · Cited by 331
Genetics and biomarkers in personalisation of lung cancer treatment
Rosell, R., Bivona, T. G., & Karachaliou, N. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61715-8 · Cited by 305
Pietrobono, S., Gagliardi, S., & Stecca, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00556 · Cited by 303
Citarella, A., Catanzaro, G., Besharat, Z. M., Trocchianesi, S., Barbagallo, F., Gosti, G., Leonetti, M., Di Fiore, A., Coppola, L., Autilio, T. M., et al. (2023) · Cancers · doi:10.3390/cancers15051471 · Cited by 27
ERK2 MAP kinase regulates SUFU binding by multisite phosphorylation of GLI1
Bardwell, A. J., Wu, B., Sarin, K. Y., Waterman, M. L., Atwood, S. X., & Bardwell, L. (2022) · Life Science Alliance · doi:10.26508/lsa.202101353 · Cited by 20
Metadata
- Authors
- Eberl, M., Klingler, S., Mangelberger, D., Loipetzberger, A., Damhofer, H., Zoidl, K., Schnidar, H., Hache, H., Bauer, H., Solca, F., Hauser‐Kronberger, C., Ermilov, A. N., Verhaegen, M. E., Bichakjian, C. K., Dlugosz, A. A., Nietfeld, W., Sibilia, M., Lehrach, H., Wierling, C., & Aberger, F.
- Venue
- EMBO Molecular Medicine
- Published
- 2012-02
- Volume
- 4
- Issue
- 3
- Pages
- 218-233
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2108961002
- Cited by
- 165
- References
- 2
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.